EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†

作者：Johannes Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, Harman Maxim Bruins, Theo M. de Reijke, Maria De Santis, Silke Gillessen, Nicholas David James, Steven J. MacLennan, Juan Palou, Tom Powles, María José Ribal, Shahrokh François Shariat, Theodorus van der Kwast, Evanguelos N. Xylinas, Neeraj Agarwal, Tom J.H. Arends, Aristotle Bamias, Alison Jane Birtle, Peter C. Black, Bernard H. Bochner, M. Bolla, Joost L. Boormans, Alberto Bossi, Alberto Briganti, Iris S. G. Brummelhuis, Max M. Burger, Daniel Castellano, Richard L. Cathomas, Arturo Chiti, Ananya Choudhury, Éva Compérat, Simon J. Crabb, Stéphane Culine, Berardino De Bari, Willem de Blok, Pieter De Visschere, Karel Decaestecker, Konstantinos Dimitropoulos, Jose Luis Dominguez-Escrig, Stefano Fanti, Valérie Fonteyne, Mark Frydenberg, Jurgen Jacobus Fütterer, Georgios Gakis, Bogdan Florin GEAVLETE, Paolo Gontero, Bernhard Grubmüller, Shaista Hafeez, Donna Elizabeth Hansel, Arndt Hartmann, Dickon Hayne, Ann M. Henry, Virginia Hernández, Harry W. Herr, Ken Herrmann, Peter Hoskin, Jorge Huguet, Barbara Alicja Jereczek‐Fossa, Rob Jones, Ashish M. Kamat, Vincent S Khoo, Anne E. Kiltie, S. Krege, Sylvain Ladoire, Pedro C. Lara, Anna M. Leliveld, Estefanía Linares-Espinós, Vibeke Løgager, Anja Lorch, Yohann Loriot, Richard Paul Meijer, Maria Carmen Mir, Marco Moschini, Hugh A. Mostafid, Arndt‐Christian Müller, Christoph Rüdiger Müller, James MO N'Dow, Andrea Necchi, Y. Neuzillet, Jorg Reinier Oddens, Jan Oldenburg, Susanne Osanto, Wim J.G. Oyen, Luís Pacheco‐Figueiredo, Helle Pappot, Manish I. Patel, Bradley Rumwell Pieters, Karin Plass, Mesut Remzi, Margitta M. Retz, Jonathan Richenberg, Michael Rink, Florian Roghmann, Jonathan E. Rosenberg, Morgan Rouprêt, Olivier Rouvière, Carl Salembier, Antti Salminen, Paul Sargos, Shomik Sengupta, Amir M. Sherif, Robert Jan Smeenk, Anita Smits, Arnulf Stenzl, George Niklaus Thalmann, Bertrand F. TOMBAL, Barış Türkbey, Susanne Vahr Lauridsen, R. Valdagni, Antoine G. van der Heijden, Hein Van Poppel, Mihai Dorin Vartolomei, Erik Veskimäe, Antoni Vilaseca, Franklin A. Vives Rivera, Thomas Wiegel, Peter N. Wiklund, Andrew C Williams, Richard E. Zigeuner, Alan Horwich · 发表于：European Urology · 年份：2019 · DOI：10.1016/j.eururo.2019.09.035 · 被引用次数：194 · 研究领域：Bladder and Urothelial Cancer Treatments、Urinary and Genital Oncology Studies、Esophageal Cancer Research and Treatment

Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts prior to voting during a consensus conference. Online Delphi survey and consensus conference. The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. Statements were ranked by experts according to their level of agreement: 1–3 (disagree), 4–6 (equivocal), and 7–9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). Overall, 116 statements were included in the Delphi survey. Of these statements, 33 (28%) achieved level 1 consensus and 49 (42%) achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance acr...